Physician profile
David A Corral
NPI 1982701009
$4,712.37
in general payments reported to CMS, 2019-2025
33 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $206 · 2021: $720 · 2022: $353 · 2023: $1,416 · 2024: $732 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058 · Honoraria: $1,000 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.70 |
| Honoraria | $1,000.00 |
| Education | $284.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Provepharm INC. | $1,142.07 | 2023 | Bludigo |
| Astellas Pharma US INC | $912.41 | 2019-2024 | Myrbetriq, Xtandi |
| Janssen Biotech, INC. | $491.83 | 2019-2025 | Erleada, Akeega, Balversa |
| Abbvie INC. | $362.11 | 2019-2025 | Lupron Depot, Botox |
| Pfizer INC. | $361.48 | 2019-2022 | |
| Boston Scientific Corporation | $247.50 | 2019-2024 | Ams 700 |
| Allergan, INC. | $144.68 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $137.36 | 2020-2025 | Caldolor |
| Myovant Sciences INC. | $98.77 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.11 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $85.80 | 2023-2024 | Orgovyx, Gemtesa |
| Merck Sharp & Dohme LLC | $81.61 | 2020-2023 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $53.73 | 2024-2025 | |
| Blue Earth Diagnostics | $42.97 | 2021-2022 | |
| Urovant Sciences INC | $34.93 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $34.74 | 2020 | |
| Olympus America INC. | $33.35 | 2024 | Soltive |
| Biotissue Holdings INC. | $32.60 | 2021 | |
| Intuitive Surgical, INC. | $31.55 | 2021 | |
| Tolmar, INC. | $31.02 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $31.02 | 2025 | Rubraca |
| Dentsply Ih INC. | $24.48 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $23.85 | 2022 | |
| Myriad Genetic Laboratories, INC. | $23.16 | 2022 | |
| Accord Healthcare, INC. | $22.72 | 2023 | |
| Antares Pharma, INC. | $22.26 | 2019 | |
| Travere Therapeutics, INC. | $21.60 | 2021 | |
| Progenics Pharmaceuticals, INC. | $19.47 | 2024 | |
| C. R. Bard, INC. & Subsidiaries | $16.23 | 2023 | Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire |
| Davol INC. | $13.75 | 2020 | |
| Coloplast Corp | $13.26 | 2022 | |
| Verity Pharmaceuticals INC. | $12.93 | 2021 | |
| Teleflex LLC | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Corral listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.